and Tram, you, good Thank everyone. afternoon,
strong year, are guidance to of this year. we subcutaneous earnings per and performance, VYVGART we We've pleased $XXX our which non-GAAP XX% on Let adding focus Phesgo This of securing and continuing revenue and with it of FDA in one the Tecentriq for go Slide of and quarter. expansion on continued also start EBITDA the growth an ranges our our we report revenue, revenue, delivery another our performance with all-time to deliver moment. was of XX% this and continued strong more revenue XX%. leading Operationally, now to adjusted high a and tenured results total to largely me will in for full third of new high detail drug our continued adoption auto-injectors high-volume royalty ENHANZE for year-to-date of record am ENHANZE revenues into and cutaneous increase small another our XX% partners enhanced DARZALEX agreements under targets the and reinforcing new million nominated broadening advancing. was the by reach partners driven strong Hytrulo. enhanced for discussions approvals Nicole technology. technology. growth regulatory X. on very new in total with quarter agreements, quarter. $XXX XX% most terms new share also our with XX% of in a expect with an X licensing royalty drug .
Notably, growth gained value financial also of EBITDA to impressive ENHANZE. delivered Roche, increased subcutaneous of delivery with amount approval our for I to Two the adjusted This reflects strong current on million. and double-digit expanded deals OCREVUS revenue, significant our Based milestones raising
large success this, And growth These our rapid volume current approvals delivery of to the expand subsidies multiple their are partners our our achievements their and trajectory. adding key of and continue leading position development illustrate programs. and geographic future reinforce predictability and platform drivers clinical They drug technology. advance well-proven in to
of into delighted and neurology. U.S. has of subcutaneous with details extended Slide X to is approval Roche's approval received we reinforce Approval approval more track regulatory for availability subcutaneous cancer which X reach XXX% TECENTRIQ anti-PDLX with OCREVUS we'll success. September, I'll delivered HYBREZA only some approvals, product our III U.S. and to Which also injection. recent an ENHANZE. all partner as further [indiscernible]. move ZUNOVO on adult these of The treatment Phase anticipated of immunotherapy. the In approval and ENHANZE and was X, indications now Tecentriq the X-minute provide partnered IV first granted represents high were with ENHANZE approximately is the a Roche's to record of announce
patients With a the year also launches significant OCREVUS simplification on their multi-hour we treatment creates us, now to subcutaneous X their to patients sclerosis outside year. and XX-minute treatment subcutaneous ZUNOVO, given compared twice and injection with intravenous the to multiple for right receive a approvals potentially This have their ENHANZE. of of given adding facility treatment recent to a an closer receive can for to add recent OCREVUS building treatment IV front infusion home. the These dramatic opportunity the of twice opportunity also a in European Tecentriq growth as
safety track commercial the have regulatory with experienced global and unmatched firsthand productive This of the move years is rapid now XX as record over subcutaneous the the approvals history This of ENHANZES they large-volume success has result and delivery. drug existing for success. conversations expansions, vehicle established who [ agreement the last a partner to me partners Let achieve ENHANZE. strong can with supporting ] standard success been
the pleased Hytrulo. are X In X hands we this their has that for ENHANZE this targets, expansion, has in Argenx the targets. quarter. target in agreement exclusively nominations to October, license nominating on ] including expanded Based by licensed We Argenx now exclusive for a total additional new in [ of VYVGART early that announced resulted X
related There to will million $XX milestone agreement, sales and targets. As per new a for are part up future progress, development X Argenx of new $XX Halozyme to make regulatory payment target. payments to attainment potential million approvals of the the
who excited are immunology. relationship Argenx to an innovative our very We in with leader expand is
closely patients through technologies. that their their improving As of we Sotesdrug rapid the is innovative our lives ] patient-centric choice large-volume commitment [ mission our of partner to for appreciate own so with drug delivery aligned delivery,
and drug additional quarter, licensing their agreement, to undisclosed global which also X our collaboration existing expanded them Viv access the target. delivery exclusive gives for In technology ENHANZE
on now that with the generating Johnson to X. starting move & our of and Slide royalty products, Now subcutaneous progress discuss Johnson milestone I'll overview, commercial with DARZALEX
frontline in opportunity with to very growth. reach a the DARZALEX almost by with increased and in the indication to indications the billion remarkable the for XX% X.X United is continued continued DARZALEX sales the outside on to are and diagnosed therapy first market lenalidomide sales basis share combination FASPRO of across XX% setting of portfolio of worldwide States with points submissions. in DARZALEX U.S. conversion in as ethane's operational and autologous rates exceeding single European further growth approvals cell DARZALEX J&J X approval was ENHANZE strong all quarter. for points quarter, multiple transplant for in United regulatory the with conversion the bortezomib, high With newly received driven announced primarily this dexamethasone. for stem Subcutaneous J&J an growth. DARZALEX ENHANZE an well share of $X DARZALEX additional an growth States. lines new In as asset quarter, DARZALEX patients gains represent additional who and with in were eligible driver recently during expanding myeloma of
company transplant ineligible. submission treatment newly and The of FASPRO is autologous with approval Food Drug who deferred of as to for a whom of announced also diagnosed myeloma indication regimen part the new DARZALEX BLA adult of Administration cell a are of for the supplemental stem for patients multiple or quadruplet the a
to shown is X XX Slide With X. to which increased countries of and that, strong to on those discussed, XX% first Phesgo demonstrate Phesgo, Phesgo, billion is strong consensus trajectory growth increased to CHF now Perjeta is Conversion the remains well now become the to I'll X.X of is now a in XX% updated Uptake is on turn for countries. Sales also and XXXX. I've launch is fixed excellent shown combination a for ENHANZE Phesgo strong projected has reach billion as Phesgo, growth momentum Roche's Also Herceptin XXXX. and with momentum. which additional analyst with launched. a exceed months by $X.X continues brand with countries the XXXX. slide in of XX% in and positioned to Perjeta revenue just conversion
As billion another for a royalty. on sales sales growth Phesgo of mid-single-digit subcutaneous this strong Halozyme all represents paid $X.X Halozyme. in opportunity has which represents
shown on X Slide X. products, now highlights Moving recent launch most Roche's to which on additional are
Hybreza. Tecentriq with start I'll
of has European IV subcutaneous XX year, of for Tecentriq intravenous the co- billion very compared the injection mentalizing to Europe, X.X subcunous conversion formulated XXXX. reported for for January that tenth to revenue eCentric that they come approximately CHF from approval the an Tecentriq allows De for in ENHANZE IV the distortion. was with of will pleased X the months XXXX. granted expect minutes of the we this indications. XX The to Following achieve $X of centric opportunity, majority stated that the U.S. sales X-minute Hybreza, all Roche adult of the first Analysts predict will in billion approval Roche's were similarly of infusion.
approval patients treatment in in of excited offers subcutaneous for of terms particularly they required The clinical Drug OCREVUS Let following to all follows with me the IV dosing. formulation neurology now OCREVUS Food approval that approval, and U.S. multiple compares from hours ENHANZE the in expect profile to reach sclerosis which June of European year. of move the patients ENHANZE This multiple the with closely Administration administration via subcutaneous occurred XX which in and strong in just time minutes the X-month and ZUNOVO. I'm expands ZUNOVO on on OCREVUS Roche's the launch this September. infusion. injection for every offers benefits
the the patients version. from patients OCREVUS to also X making ZUNOVO regarding for on are expand not The it as commented OCREVUS that availability market coming switches opportunity burden from and X the confident which U.S., increased are revenue opening the the to hospitals administration quarterly [indiscernible] XX% of first sales has at signals to will driven billion formulation promising with an they to X to all new to who the up represent treatment. While seeing supporting that ZUNOVO sclerosis receive an OCREVUS treatment in for the also convert About multiple Roche's OCREVUS's $X for sees expansion. OCREVUS the months recent is by starts has new who subcutaneous they easing of treatment. incremental smaller regions. brand the community of in X% opportunity. market it of that year, are billion example, IV. call from possible are ENHANZE by receiving on subcutaneous first commented patients uptake Roche's easier are footprint an opportunity CHF and the travel Which IV makes
Mycena now grow shown strong to recently access move We're me to of providers will generalized with center. momentum [ guard in VYVGART live easy including first the expect to Hytrulo, patients VYVGART VYVGART is ENHANZE with subcutaneous bringing switching commented and its on new in physicians importance indication to Argenx in Let they to Argenx is patients, Slide oral which VYVGART X. ]. with and subcutaneous continues that an subcutaneous gravis experience is by pleased who and from market already medications infusion expanding payers. IV don't that patients patients Argenx have
now polyneuropathy. to demyelinating Moving chronic inflammatory
expects for a while Argenx than the The also patients need, second CIDP for high what happy a with launch Energenic April globally. preprefilled of CIDP. patients increasing to more has filing for similar medical XX patients recent, BLA expand its in also ENHANZE, administration to gravis. in ENHANZE GMP Organic and with a date was -- awareness We're China, broad convenient syringe that presence introduce amongst XXXX. accomplished for also option the with approvals and in their forward unmet of access the additional has to subcutaneous commented to has the of approval to regions. its action continued myasthenia syringe is VYVGART create to will countries Hytrulo indication physicians. fast with more they prefilled option XX, efgartigimod for they recently, and which JMG see for launch are PDUFA number The subcutaneous in approved Most looking
evaluating be supporting where strong almost advance product for strategy to total is believe its continues over syringe We're the total opportunity X eye VYVGART registrational just indications VYVGART, $X studies pleased billion there time. an for there VYVGART by XXXX argenx in to administered X addressable reach approved prefilled the is currently Hytrulo of to project expanding in high multiple unmet with Given to ENHANZE indications. as fairly pipeline market We disease, by additional thyroid considerable launch the to first analysts the sales and increase need. indication
in Argenx Phase October, a ocular initiated kidney with And also III evaluating trial argenx Phase antibody-mediated Hytrulo for ENHANZE in recipients a addition, with gravis. recently, rejection. myasthenia VYVGART II study In transplant initiated
Hytrulo, Now has pervert [ Argenx beyond multi-indication ] pipeline assets robust a VYVGART ARGX-XXX. or mass of including
success the point was value As committed VYVGART in of subcutaneous delivery. an of patients' benefit of the improving The recognizing forefront lives, strong early proof innovator Hytrulo to proposition the Argenx a at volume we nominations to expanded delivery. be from to subcutaneous to pleased of drug X large their ENHANZE-enabled choice have delivery. are X agreement our partner very argenx for subcutaneous of with And and rapid is
projects review. sales. represent now Nivolumab the for both with a exploratory also the subcutaneous. ENHANZE Nivolumab partner stated is OPDIVO, granted currently are with sales. this of with Amivantamab also, potential Amivantamab X-minute which Nivolumab. this priority treatment results & subcutaneous billion move approval awaiting the U.S. administration compared subcutaneous review to with fivefold regulatory PDUFA Nivolumab X subcutaneous approved products the will and They time. of indications would that rate stated acceptance from and to Squibb, treatment ninth Nivolumab is is December subcutaneous represent pending I'll would in highlighted also subcutaneous Earlier the that Johnson's tenth for trial FDA. Once Johnson launch. PALOMA-X expect revealed a has product update approved, the arm. an under regulatory ENHANZE, analysis, it the European subcutaneous submission the annual regulatory the of for patients IV The me Let improved than XX of year, between for in of time. our ENHANZE. is last filing date represent The to the currently benefit intravenous an is infusion-related quarter to an reactions and product. presented approval in our with Bristol has launched in Bristol-Myers to name at with this Slide overall data reduction ASCO. brand presented begin a Bristol a they under IV $X XX% action ENHANZE which Approval exciting to that also year. total reduction XX% Nivolumab subcutaneous XX% physicians with convert survival And fivefold treatment they received for was presenters with less as
earnings what is billion than in which for This be their analysts and the total and During in revenue launched analysts name billion What Riverbend, of exciting terms is soon products in a believe highlighted brand clearly that the J&J is the underappreciated largest opportunity projections call, X according is larger they estimating this IV back are assets X XXXX. the represent Amivantamab decade. almost and their versus $XX DARZALEX of brand even last opportunity recently X launched portfolio an to half where FASPRO that to subcutaneous of for estimates. analyst represents in $XX company opportunity projections are currently
result in clearly mid-single-digit receives significant add you subcutaneous to projecting on XXXX. see Halozyme As how the $X achieve than a royalty -- will greater revenue next and products in sales can over and our revenue average years billion in these royalty
Bristol-Myers of and positioned that clinical to to advancements, our their exciting the and double-digit top strong of we primary and the potential years. to which cell move on just approved now TAK-XXX, launch III AG for in me launches in XX, all line IV future III advance lung deliver Relatlimab highlights the Let the products. Takeda advance our our their the continue this plus coming in Phase is already of a brand has study With non-small mention with growth study Phase XX% Nivolumab are I'll continued cancer. Slide growth well is has beginning III continues for bottom approved a some where few [ of immunodeficiency. ]. candidate, also The first-line combination treatment Dulac continued progressing regulatory of to trial and are with product, product name ENHANZE Phase to
some and to intellectual on now Let property. make me Slide transition XX, I'll comments
Patent patent estate continue take and portfolio. for Our new extensive to IP durability XXXX. supports currently European streams, In our our will revenue patent extend granted be and Office, confident have pending we we June, we're of the in to to update resulted an our by to which the States coverage patent were patent that guidance. of protect our region extended ENHANZE in United March a that the granted. technology in We a similar This X, reissue actions
reissue of look not pioneer financial And which granted subcutaneous we as to that outlook broadly We very were if developing introduce there. an our for leronodates. did with forward updated patent in we patent Notably, MDA's we that medicines, claims. human portfolio hyaluronidases to human a Halozyme high first covers providing activate was high ENHANZE. similar is created administration Neutrop, the modified human that aromatase stop excited soluble call
thousands years technology cover modifications. other by created and ENHANZE work license of of and patents many created experiments, We the comprehensive from we and we and and hyaluronidase are projects that a over research and modifications, library that continue This to MD's our those thousands which the innovate And truncated experiment. characterize human we large distinct the protected the patents, as groundbreaking technology.
why No. discussing are the There X really key are reasons. MD's portfolio? Now we
issued pending been to total and multiple MDA patents. and wanted from to Bringing the we end distinguish new avoid recently patents ENHANZE to XXX, we've granted Firstly, any the confusion. nearly the
enable for administration. our intellectual opportunities as forward the are always Secondly, ENHANZE patients. new looking conversion technology licensor, The new an and we help therapies and of solutions to to derisked therapies property that commercialize others discoveries IV gold bring standard to to is for subcutaneous
to in recognize be biologic or they do wish use utilize modified Halozyme select hand. not But utilizing our impact ENHANZE are or that cases might in able up property. MDA we or do the Halozyme and opportunities every now open would that to intellectual business. drug supplier However, available do to and license new for not those patents laronadies high that pioneering It's for
more over detail. discuss the in hand who our financial call Nicole, to now results will I'll
